Answer a few simple
questions to determine which of your formulas help meet your patient's
parenteral nutrition goals


The following are online resources from professional
associations, government entities, and consumer organizations that
provide more information on parenteral nutrition in the health care
setting. Baxter Healthcare Corporation does not review or control the
content of any non-Baxter site. Baxter Healthcare Corporation does not
endorse and is not responsible for the accuracy, content, practices or
standards of any non-Baxter sources. You may, however, find these links
useful in your search for information.

Indications
CLINIMIX and CLINIMIX E Injections are indicated as a caloric
component in a parenteral nutrition regimen and as the protein
(nitrogen) source for offsetting nitrogen loss or for treatment of
negative nitrogen balance in patients where:
- The alimentary tract cannot or should not be used,
- Gastrointestinal absorption of protein is impaired, or
- Metabolic requirements for protein are substantially
increased, as with extensive burns.
Important Risk Information
- It is essential that a carefully prepared
protocol based on current medical practices be followed, preferably by
an experienced team. Frequent clinical evaluation and laboratory
determinations are necessary for proper monitoring during
administration.
- CLINIMIX and CLINIMIX E Injections are contraindicated in
patients having intracranial or intraspinal hemorrhage, in patients who
are severely dehydrated, in patients hypersensitive to one or more
amino acids and in patients with severe liver disease or hepatic coma.
Solutions containing corn-derived dextrose may be contraindicated in
patients with known allergy to corn or corn products.
- Because of the potential for life-threatening events, caution
should be taken to ensure that precipitates have not formed in any
parenteral nutrient admixture.
- Use with caution when administering to patients with anuria or
renal insufficiency, pulmonary insufficiency, or heart disease. The
intravenous administration of these solutions can cause fluid and/or
solute overloading resulting in dilution of serum electrolyte
concentrations, overhydration, congested states, or pulmonary edema.
- Metabolic complications have been reported, such as acid-base,
electrolyte, and blood glucose imbalances, elevated liver enzymes, and
osmotic diuresis and dehydration.
- Other adverse reactions that may occur include febrile
response, infection at the site of injection, extravasation, and
hypervolemia. The infusion of hypertonic nutrient injections into a
peripheral vein may result in vein irritation, vein damage, and
thrombosis.
- This product contains aluminum that may be toxic with
prolonged parenteral administration if kidney function is impaired.
- CLINIMIX and CLINIMIX E Injections must be
admixed prior to infusion.